BC Week In Review | Apr 15, 2013
Clinical News

Hyseq Inc. regulatory update

HYSQ received U.S. Patent No. 5,695,940 covering a method for partial sequencing of DNA by hybridization of oligonucleotide probes. (HYSQ files suit against AFFX, see B6) Hyseq Inc. (HYSQ), Sunnyvale, Calif.   Business: Enabling technology...
BC Week In Review | Apr 15, 2013
Company News

Hyseq Inc., Perkin-Elmer Corp. deal

The companies will develop a "universal" gene assay chip using Hyseq's DNA HyChip technology and Perkin-Elmer's DNA analysis technology. The Hyseq chip begins with a set of universal probes that can perform half of the...
BioCentury | May 21, 2012
Strategy

Remembrance: The Titan who changed our lives

Remembrance: The Titan who changed our lives For those of us who entered the biotech industry in the 1980s, George Rathmann already was a living legend. And those of us who knew him consider ourselves...
BioCentury | Jun 18, 2007
Tools & Techniques

Nuvelo's stealth target

Ever since Nuvelo Inc. was formed through the merger of Hyseq Pharmaceuticals Inc. and Variagenics Inc. in 2003, the company's clinical focus has been on compounds in-licensed from third parties. Although it's been relatively silent...
BioCentury | Mar 27, 2006
Finance

Ebb & Flow

BioMarin (BMRN; SWX:BMRN) last week tapped the debt and equity markets to the tune of $267 million in a follow-on and senior subordinated note deal. The financings punctuate the end of BMRN's pediatric detour, and...
BioCentury | Sep 6, 2004
Strategy

Back to School: Asset accumulation

A few months ago, BioCentury spilled a lot of ink to deconstruct the NRDO model of no-research, development only companies being formed to scavenge for products or technologies that can be commercialized quickly and offer...
BC Extra | Apr 13, 2004
Company News

Gloucester names Mohr CEO

Gloucester (Cambridge, Mass.) hired Joseph Mohr as president, CEO and a director. Mohr previously was president and CBO of Variagenics , which merged with Hyseq to become Nuvelo (NUVO). Gloucester , which was founded in 2003, is...
BioCentury | Feb 9, 2004
Strategy

Nuvelo's bargain basement pipeline

In October 2001, Nuvelo Inc. , then called Hyseq Inc., spun out its original array business to refocus on drug development. It had $16.5 million in the bank and a discovery-stage pipeline. With its most recent...
BC Extra | Oct 2, 2003
Financial News

Nuvelo raises $24.5 million

NUVO raised $24.5 million in a private placement of 10 million shares at $2.45. JMP Securities served as the underwriter. NUVO's alfimeprase thrombolytic is in Phase II testing to treat peripheral arterial occlusion. The compound...
BC Week In Review | Mar 3, 2003
Company News

Nuvelo cardiovascular news

NUVO said it is refocusing it development plans on its alfimeprase thrombolytic compound, which is partnered with Amgen Inc. (AMGN, Thousand Oaks, Calif.) and is in Phase I testing for peripheral arterial disease (PAD). As...
Items per page:
1 - 10 of 163
BC Week In Review | Apr 15, 2013
Clinical News

Hyseq Inc. regulatory update

HYSQ received U.S. Patent No. 5,695,940 covering a method for partial sequencing of DNA by hybridization of oligonucleotide probes. (HYSQ files suit against AFFX, see B6) Hyseq Inc. (HYSQ), Sunnyvale, Calif.   Business: Enabling technology...
BC Week In Review | Apr 15, 2013
Company News

Hyseq Inc., Perkin-Elmer Corp. deal

The companies will develop a "universal" gene assay chip using Hyseq's DNA HyChip technology and Perkin-Elmer's DNA analysis technology. The Hyseq chip begins with a set of universal probes that can perform half of the...
BioCentury | May 21, 2012
Strategy

Remembrance: The Titan who changed our lives

Remembrance: The Titan who changed our lives For those of us who entered the biotech industry in the 1980s, George Rathmann already was a living legend. And those of us who knew him consider ourselves...
BioCentury | Jun 18, 2007
Tools & Techniques

Nuvelo's stealth target

Ever since Nuvelo Inc. was formed through the merger of Hyseq Pharmaceuticals Inc. and Variagenics Inc. in 2003, the company's clinical focus has been on compounds in-licensed from third parties. Although it's been relatively silent...
BioCentury | Mar 27, 2006
Finance

Ebb & Flow

BioMarin (BMRN; SWX:BMRN) last week tapped the debt and equity markets to the tune of $267 million in a follow-on and senior subordinated note deal. The financings punctuate the end of BMRN's pediatric detour, and...
BioCentury | Sep 6, 2004
Strategy

Back to School: Asset accumulation

A few months ago, BioCentury spilled a lot of ink to deconstruct the NRDO model of no-research, development only companies being formed to scavenge for products or technologies that can be commercialized quickly and offer...
BC Extra | Apr 13, 2004
Company News

Gloucester names Mohr CEO

Gloucester (Cambridge, Mass.) hired Joseph Mohr as president, CEO and a director. Mohr previously was president and CBO of Variagenics , which merged with Hyseq to become Nuvelo (NUVO). Gloucester , which was founded in 2003, is...
BioCentury | Feb 9, 2004
Strategy

Nuvelo's bargain basement pipeline

In October 2001, Nuvelo Inc. , then called Hyseq Inc., spun out its original array business to refocus on drug development. It had $16.5 million in the bank and a discovery-stage pipeline. With its most recent...
BC Extra | Oct 2, 2003
Financial News

Nuvelo raises $24.5 million

NUVO raised $24.5 million in a private placement of 10 million shares at $2.45. JMP Securities served as the underwriter. NUVO's alfimeprase thrombolytic is in Phase II testing to treat peripheral arterial occlusion. The compound...
BC Week In Review | Mar 3, 2003
Company News

Nuvelo cardiovascular news

NUVO said it is refocusing it development plans on its alfimeprase thrombolytic compound, which is partnered with Amgen Inc. (AMGN, Thousand Oaks, Calif.) and is in Phase I testing for peripheral arterial disease (PAD). As...
Items per page:
1 - 10 of 163